Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cancer treatment sarcomatoid carcinoma tumor
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by

Cancer Treatment Sarcomatoid Carcinoma Tumor Articles & Analysis

614 news found

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the expansion of its custom services to include the synthesis of Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles (MNPs). These customized magnetic particles can be conjugated with the biologically targeted small molecules desired by researchers, and have a uniform size and shape, ...

ByCD Bioparticles


CD Bioparticles Launches Purified Exosomes for Drug Delivery and Therapeutic Research

CD Bioparticles Launches Purified Exosomes for Drug Delivery and Therapeutic Research

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the availability of its quality Purified Exosomes to support research in drug delivery, regenerative medicine, and various therapeutic applications. Exosomes are extracellular vesicles secreted by human cells that exhibit biofilm characteristics. They have a particle size of 30-150 ...

ByCD Bioparticles


Breakthroughs in Neurology and Oncology: Advancing Patient Well-Being with Innovative Therapies

Breakthroughs in Neurology and Oncology: Advancing Patient Well-Being with Innovative Therapies

Medical science is witnessing remarkable advancements in neurology and oncology, with cutting-edge technologies shaping the future of patient care. Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. In dermatology, new methods for treating benign epidermal lesions are ...

ByContent Management Test Company. Sugar


Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

Alfa Chemistry is one of the leading chemical manufacturers and suppliers who has been able to maintain its leadership position in the pharmaceutical sector by offering a broad product portfolio that caters to all aspects of the drug creation process. Always innovative and outstanding, Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building ...

ByAlfa Chemistry


Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

This year Protheragen-ING has extended its portfolio of Active Pharmaceutical Ingredients (APIs) to include several hundred new varieties, catering to a broad spectrum of therapeutic needs such as anti-tumor, hypoglycemic, antipsychotic, bronchiectasis, and antihypertensive treatments. Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of ...

ByProtheragen-ING


SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...

BySOPHiA Genetics


Huateng Pharma: Empowering ADC Development with Premium Monodispersed PEGs

Huateng Pharma: Empowering ADC Development with Premium Monodispersed PEGs

Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. is proud to provide high-quality monodispersed polyethylene glycols (PEGs) tailored for the evolving needs of antibody-drug conjugates (ADCs). With the ADC market surpassing $10 billion in 2023 and projected to reach $13.13 billion by 2030, our commitment to innovation and quality is stronger than ever. Among the 15 approved ADCs ...

ByHunan Huateng Pharmaceutical Co. Ltd.


ECP Posters spotlight

ECP Posters spotlight

In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...

BySOPHiA Genetics


SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will ...

BySOPHiA Genetics


Alfa Chemistry Expands Portfolio with Diverse Alkaloids-Related Natural Products for Health, Nutrition Enhancement

Alfa Chemistry Expands Portfolio with Diverse Alkaloids-Related Natural Products for Health, Nutrition Enhancement

Alfa Chemistry, a recognized leader in the alkaloid industry, has expanded its offerings to include a comprehensive range of alkaloids-related natural products. This expansion underscores its commitment to providing high-quality compounds for various applications in medicine, food, and cosmetics. The suite of products now includes saccharides, flavonoids, terpenoids, phenylpropanoids, ...

ByAlfa Chemistry


Invasive Mold Infections and Protecting the Immunocompromised in High-Risk Environments

Invasive Mold Infections and Protecting the Immunocompromised in High-Risk Environments

Almost anyone with a weakened or suppressed immune system could be at a heightened risk of developing an invasive mold infection (IMI). Two of the most common IMIs include invasive aspergillosis and invasive mucormycosis. The Centers for Disease Control and Prevention (CDC) warns that IMIs can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to ...

ByCochrane & Associates, LLC


AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F1885 System

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F1885 System

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for ...

ByAngioDynamics, Inc.


Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research   

Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research  

Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...

ByAlfa Cytology


Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

The New York State Department of Health (NYSDOH) describes enterococci as part of the normal flora in the intestinal tract and also a common cause of nosocomial infections. The bacteria can also often found in the natural environment, in soil and water. The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly finding new ways to avoid the effects of the ...

ByCochrane & Associates, LLC


DOE to Play Key Role in National Artificial Intelligence Research Resource Pilot

DOE to Play Key Role in National Artificial Intelligence Research Resource Pilot

The U.S. Department of Energy announced this week (Jan 24) that it will play a key role in the National Artificial Intelligence Research Resource (NAIRR) pilot as part of President Biden's push to ensure the United States is a leader in harnessing the promise and managing the risks of artificial intelligence (AI). This pilot, led by the U.S. National Science Foundation (NSF), aims to develop a ...

BySmart Grid Observer


AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...

ByAngioDynamics, Inc.


CD Genomics Unveils Cutting-Edge 5mC/5hmC Sequencing Service to Drive Epigenomics Research Forward

CD Genomics Unveils Cutting-Edge 5mC/5hmC Sequencing Service to Drive Epigenomics Research Forward

CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision ...

ByCD Genomics


Biopharma PEG Assists ADC Development with Monodispersed PEGs

Biopharma PEG Assists ADC Development with Monodispersed PEGs

Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. Notable PEGs include mPEG36-NH2, NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA, and more.ADCs ...

ByBiopharma PEG Scientific Inc


Protecting the Immunocompromised from Invasive Mold Infection Risks in Hospitals and Buildings throughout Puerto Rico

Protecting the Immunocompromised from Invasive Mold Infection Risks in Hospitals and Buildings throughout Puerto Rico

Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...

ByCochrane & Associates, LLC


Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...

ByCELLINK

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT